La thiorédoxine n'est pas un marqueur pour la dépression de la résistance au traitement mais associée à une fonction cognitive: une étude sur le rTMS.

Aperçu: G.M.

On sait que le stress oxydatif élevé joue un rôle important dans le développement de la dépression et du dysfonctionnement cognitif. À ce jour, la thiorédoxine (TRX), une protéine antioxydante, a été étudiée comme marqueur pour les troubles psychiatriques tels que la schizophrénie, le trouble bipolaire et l'autisme, mais sa relation avec la dépression est encore être inconnue.  

Les résultats indiquent que les niveaux de TRX ne peuvent pas être utilisés comme marqueur pour le traitement des dépressions résistantes aux traitements.  

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 22. pii: S0278-5846(16)30464-X. doi: 10.1016/j.pnpbp.2017.04.025.

Thioredoxin is not a marker for treatment-resistance depression but associated with cognitive function: An rTMS study

Aydın EP¹, Genc A², Dalkıran M², Uyar ET², Özer ÖA², Karamustafalıoğlu KO².

Author information

1

Department of Psychiatry, Şişli Hamidiye Etfal Teaching and Research Hospital, Istanbul, Turkey. Electronic address: efruzpirdogan@gmail.com

2

Department of Psychiatry, Şişli Hamidiye Etfal Teaching and Research Hospital, Istanbul, Turkey.

Abstract

Elevated oxidative stress is known to play an important role in development of depression and cognitive dysfunction. To date, thioredoxin (TRX), an antioxidant protein, has been investigated as a marker for psychiatric disorders such as schizophrenia, bipolar disorder and autism but its relationship with depression is yet to be unknown. The aim of this study is to detect the TRX levels in patients with treatment-resistant depression (TRD), analyse the effect of rTMS (repetitive transcranial magnetic stimulation) application on TRX levels and display the relationship of TRX with cognitive areas. This study included 27 treatment-resistant unipolar depression patients and 29 healthy subjects. Patients were evaluated by Hamilton Depression Scale (HDRS), Hamilton Anxiety Scale (HARS) and Montreal Cognitive Assessment (MoCA) before and after rTMS application. 23 of TRD patients were applied high-frequency rTMS over left DLPFC for 2 to 4weeks and plasma TRX levels of patients and healthy subjects were measured. No significant difference was determined between the TRX levels of patients and healthy subjects (p>0.05). After rTMS application there were significant decrease in severity of depression (p<0.001) and anxiety (p<0.001), and explicit improvement in cognitive areas (delayed memory, visual-spatial/executive abilities and language points) (all p<0.05). No difference was detected in TRX levels of the patients after rTMS application (p>0.005). High language scores of the patients were found to be associated with high TRX levels (p<0.005). Our study indicates that TRX levels cannot be used as a marker for TRD or rTMS treatment in TRD. In spite of this TRX levels have a positive correlation with language functions of the patients of TRD. More extensive studies are required to clarify the mechanism of action of TRX and the effect of TRX on cognitive functions.

Copyright © 2017. Published by Elsevier Inc.

PMID: 28442424

DOI: 10.1016/j.pnpbp.2017.04.025